Leukaemia (chronic myeloid) - imatinib: review decision-October 2014 information
History
Documents created during the development process.
Background information
-
-
Leukaemia (chronic myeloid) - imatinib: appendix a-GE decision paper-October 2014
-
Leukaemia (chronic myeloid) - imatinib: appendix a-GE decision paper-October 2014 (PDF 111 KB)
-
TA70 Leukaemia (chronic myeloid) - imatinib: review proposal August 2014 information
-
TA70 Leukaemia (chronic myeloid) - imatinib: appendix a - provisional matrix of stakeholders
-
-
TA70 Leukaemia (chronic myeloid) - imatinib: appendix b - proposal paper presented to the Institute's Guidance Executive
-
-
-
Review decision - July 2009 appendix 1: proposal comment summary table
-
Review decision - July 2009 appendix 1: proposal comment summary table (PDF 43 KB)
-
-
Review proposal: May 2009, Appendix A - provisional matrix
-
Review proposal: May 2009, Appendix A - provisional matrix (PDF 47 KB)
-
-
Leukaemia (chronic myeloid) - imatinib: review decision information
Final Appraisal Determination: Imatinib for chronic myeloid leukaemia
Appraisal Consultation Document: Imatinib for chronic myeloid leukaemia
Scope: Imatinib for Chronic Myeloid Leukaemia (first line therapy)
Protocol: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase
-
Protocol: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase
-
Assessment Report: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase
-
Assessment Report: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase
-